TORONTO, Aug. 26 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK (less than)http://innp.pk/(greater than) - News) is pleased to announce early stage discussions with interested funding sources.
With the recent FDA approval of the drugs Lyrica (marketed by Pfizer Inc.), and Cymbalta (marketed by Eli Lilly and Co.) for the chronic pain condition of fibromyalgia ('Approved Drugs' http://www.fda.gov/consumer/updates/fibromyalgia062107.html) funding and capital sources have a growing interest in the chronic pain market and the blockbuster opportunity Innolife Pharma Inc. represents.
Fibromyalgia affects 2 to 4 percent of the population, according to the American College of Rheumatology (ACR) and according to studies, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year.
The therapies being licensed by Innolife Pharma Inc. are clinically proven to be effective for fibromyalgia, as well as: low back pain; neck pain; osteo-arthritis; sciatica; migraines; headaches; and D.D.D.
"Over the last few months, we have received interest from a few funding sources in our breakthrough treatment for chronic pain sufferers." said Mr. Schiller, the President of Innolife Pharma Inc. "Fibromyalgia is one of the chronic pain conditions that we see a lot of and have clinically proven to be very effective."
With strong consumer aversion to drug side effects and the high sensitivity to label warnings, Innolife Pharma Inc. represents the chronic pain treatment of choice that consumers are seeking.
The funding being discussed will help to expand Innolife Pharma Inc. clinics and provide patients with the non-prescription chronic pain treatment sought after, in a trusted National brand.
About Innolife Pharma Inc.
Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi- discipline medical group focusing on licensing the Natural Pain Relief Center all- non-narcotic proprietary breakthrough in the treatment of chronic pain.
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
SOURCE Innolife Pharma Inc.